38th week of 2012 patent applcation highlights part 48 |
Patent application number | Title | Published |
20120238438 | DIELECTRIC CERAMIC COMPOSITION - A dielectric ceramic composition comprising a main component and at least one or more subcomponent elements has a dielectric particle and a grain boundary. The dielectric particle has a main component phase substantially composed of the main component, and a diffusive phase around the main component phase where at least one selected from the subcomponent elements is diffused, a local minimal value of Cs is located at an outside edge side with respect to a position of the local maximum value of Cs, and Cs is increased from a position of the local minimal value of Cs toward the outside edge, when the dielectric particle is cut on an arbitrary cutting plane including the main component phase, and Cs is defined as a concentration of one or more elements selected from the subcomponent elements in an arbitrary position in the dielectric particle. | 2012-09-20 |
20120238439 | SILICON-RICH ALLOYS - Castable silicon-based compositions have enhanced toughness and related properties compared to silicon. The con-based compositions comprise silicon at a concentration greater than 50% by weight and one or more additional elements in structure comprising a cubic silicon phase and an additional phase which may impart toughness through mechanisms related to plastic flow or crack interaction with interfacial boundaries. | 2012-09-20 |
20120238440 | Low Platinum Fuel Cells, Catalysts, and Method for Preparing the Same - This invention provides novel fuel cell electrodes and catalysts comprising a series of catalytically active thin-film metal alloys with low platinum concentration supported on nanostructured materials (nanoparticles). Processing of the electrodes and catalysts can include electrodeposition methods, and high-pressure coating techniques. In certain embodiments, an integrated gas-diffusion/electrode/catalyst layer can be prepared by processing catalyst thin films and nanoparticles into gas-diffusion media such as Toray or SGL carbon fiber papers. The catalysts can be placed in contact with an electrolyte membrane for PEM fuel cell applications. | 2012-09-20 |
20120238441 | Size-selective hemocompatible polymer system - A size-selective hemocompatible porous polymeric adsorbent system is provided, the polymer system comprises at least one crosslinking agent and at least one dispersing agent, and the polymer has a plurality of pores with diameters in the range from about 17 to about 40,000 Angstroms | 2012-09-20 |
20120238442 | NANOPARTICLES INCLUDING METAL OXIDE HAVING CATALYTIC ACTIVITY - Core-shell nanoparticles having a core material and a mesoporous silica shell, and a method for manufacturing the core-shell nanoparticles are provided. | 2012-09-20 |
20120238443 | MANUFACTURE OF BASE METAL NANOPARTICLES USING A SEED PARTICLE METHOD - The present invention is directed to a process for manufacture of base metal nano-particles using precious metal seed particles. | 2012-09-20 |
20120238444 | POWDER, METHOD OF PRODUCING POWDER AND ADSORPTION APPARATUS - The present invention is powder constituted from particles of a compound represented by the following general formula (1), (Ca | 2012-09-20 |
20120238445 | POROUS SIO2-XEROGEL WITH A CHARACTERISTIC PORE SIZE, STABLE DRYING PRECURSORS THEREOF AND USE OF SAME - A porous SiO2 xerogel is produced using temporary pore fillers or solid skeletal supports, which are removed by thermal oxidation at the end of the production process (e.g. carbon or organic), by means of a sol-gel-process by subcritical drying of the gel. The SiO | 2012-09-20 |
20120238446 | REVERSIBLE THERMOSENSITIVE RECORDING MEDIUM AND REVERSIBLE THERMOSENSITIVE RECORDING MEMBER - A reversible thermosensitive recording medium including: a support; a reversible thermosensitive recording layer on the support; and a protective layer on the reversible thermosensitive recording layer, wherein the reversible thermosensitive recording layer contains an electron-donating color-forming compound and an electron-accepting compound, wherein the protective layer contains a polyester acrylate resin, and wherein the protective layer has a glass transition temperature of 230° C. or higher and has an elongation of 10% or higher. | 2012-09-20 |
20120238447 | Pesticidal Mixtures of Triazamate with Strobilurines - The present invention relates to synergistic mixtures comprising, as active components,
| 2012-09-20 |
20120238448 | METHOD FOR TREATING PHYTOPATHOGENIC MICROORGANISMS USING SURFACE-MODIFIED NANOPARTICULATE COPPER SALTS - The present invention relates to a method for controlling phytopathogenic microorganisms by treating the crop to be protected, the soil or the plant propagation material with an effective amount of copper salt particles which comprise a water-soluble polymer and which have a primary particle diameter of from 1 to 200 nm. The invention also relates to an aqueous suspension of the abovementioned copper salt particles and the use of this suspension in crop protection. | 2012-09-20 |
20120238449 | SYNERGISTIC HERBICIDAL COMPOSITION CONTAINING PENOXSULAM AND PYROXSULAM - A synergistic mixture of penoxsulam and pyroxsulam controls weeds in rice, cereal and grain crops, tree and vine crops, pome, stone and citrus crops, pastures, rangelands, industrial vegetation management (IVM), and turf. | 2012-09-20 |
20120238450 | C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS - The present invention relates to novel c2-phenyl-substituted cyclic ketoenols, to a plurality of processes for their preparation and to their use as pesticides as herbicides. | 2012-09-20 |
20120238451 | HERBICIDE AND ADJUVANT COMPOSITIONS AND METHOD OF USE THEREOF - The invention provides methods and herbicide compositions for weed control. The invention provides for enhancement of herbicide activity by the addition of an adjuvant. The herbicide activity is especially useful as a preplant and postplant treatment. | 2012-09-20 |
20120238452 | CHEMICAL COMPOUNDS AND THEIR USE AS PESTICIDES - Compounds of the formula (I), wherein the substituents are as defined in claim | 2012-09-20 |
20120238453 | Supported Superconducting Magnet - A supported superconducting magnet includes a superconducting magnet arranged within an outer vacuum container and a support structure bearing the weight of the superconducting magnet against a support surface. The support structure includes a tubular suspension element located between the magnet and the support surface, the tubular suspension element retaining the magnet in a fixed relative position with reference to the outer vacuum container by means of complementary interface surfaces arranged to transmit the weight of the superconducting magnet to the support structure. The tubular suspension element is arranged about a generally vertical axis, and supports a solenoidal magnet structure which is arranged about a generally horizontal axis. | 2012-09-20 |
20120238454 | SUBSTRATE FOR OXIDE SUPERCONDUCTOR AND PROCESS FOR PRODUCING SAME, AND OXIDE SUPERCONDUCTOR AND PROCESS FOR PRODUCING SAME - A substrate for an oxide superconductor including: a metal base; an interlayer of MgO formed on the metal base by ion beam assisted deposition method (IBAD METHOD); and a cap layer that is formed directly on the interlayer and has a higher degree of crystal orientation than that of the interlayer, in which the interlayer of MgO is subjected to a humidity treatment prior to formation of the cap layer. | 2012-09-20 |
20120238455 | METHOD FOR DIAGNOSING DRUG ERUPTION RISK INDUCED BY ANTIEPILEPTIC DRUG BASED ON SINGLE NUCLEOTIDE POLYMORPHISM IN 21.33 REGION OF SHORT ARM OF CHROMOSOME 6 - The genotype of a single nucleotide polymorphism (SNP) existing in the 21.33 region of the short arm of chromosome 6, such as an SNP at the HLA-A locus, is analyzed, and, based on the results, drug eruption risk induced by an antiepileptic drug is diagnosed. | 2012-09-20 |
20120238456 | RATIONAL LIBRARY - The invention relates to a method to generate rational libraries comprising genetic elements which are involved in transcriptional and/or translational regulation of a gene and devised to increase the production yield of the encoded protein as well as to the rational library and to the application of said rational library. | 2012-09-20 |
20120238457 | RNA ANALYTICS METHOD - The present invention relates to a method of ordering nucleic acid molecule fragment sequences derived from a pool of potentially diverse RNA molecules comprising
| 2012-09-20 |
20120238458 | Novel tumor marker determination - A method of determining gynaecologic tumor disease in a subject by providing a sample of peripheral blood of the subject, measuring the PPIC expression of cells in the sample, and comparing this to a reference value, the PPIC overexpression being indicative of a gynecologic tumor disease and/or disease progression, including metastatic potential in a gynecologic cancer patient. | 2012-09-20 |
20120238459 | METHOD FOR PREDICTING THERAPEUTIC EFFECT ON CHRONIC HEPATITIS C - A method for predicting therapeutic effect of combination therapy with peginterferon and ribavirin in chronic hepatitis C therapy, comprising:
| 2012-09-20 |
20120238460 | RANTES LEVELS AS A DIAGNOSTIC AND THERAPEUTIC FOR ACUTE GRAFT VERSUS HOST DISEASE - Disclosed herein are methods for determining the likelihood of a subject to develop Acute graft versus host disease (aGVHD) upon receiving myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). One such method comprises assaying for baseline plasma concentration of RANTES in a sample obtained from the subject, and comparing the baseline plasma concentration of RANTES to a predetermined level. The method may further comprise assaying for day 7 plasma concentration of RANTES in sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for day 7 plasma concentration of RANTES in a sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for donor plasma concentration of RANTES in a sample obtained from a donor of the hemtopoietic stem cells, and comparing the donor plasma concentration of RANTES to a predetermined level, wherein a donor plasma concentration of RANTES less than the predetermined level indicates a likelihood of the subject to develop aGVHD upon receiving myeloablative allogeneic HSCT from that donor. Other methods include assaying for day 0, or for day 7, plasma concentration of MCP-1 in a sample obtained from the subject, and comparing the day 0 or day 7, plasma concentration of MCP-1 to a predetermined level. | 2012-09-20 |
20120238461 | METHOD FOR DETERMINING THE RISK OF OCCURRENCE OF ALZHEIMER'S DISEASE - The present invention relates to an in vitro method for determining that an individual is at risk of developing Alzheimer's disease, which comprises: —determining whether the individual harbours at least one variant allele of a susceptibility gene selected from the apolipoprotein J gene (APOJ) and the complement component receptor 1 gene (CR 1); —deducing that if the individual harbours at least one variant allele of the APOJ and/or CR1 gene, then the individual is at risk of developing Alzheimer's disease. | 2012-09-20 |
20120238462 | METHODS FOR REGULATING THE GROWTH AND/OR SURVIVAL OF TUMOR CELLS AND STEM CELLS BY MODULATING THE EXPRESSION OR FUNCTION OF THE TRANSCRIPTION FACTORS ATF5 - The present invention provides methods for regulating the growth and/or survival of tumor cells and stem cells by modulating the expression or function of ATF5. | 2012-09-20 |
20120238463 | LINE-1 Hypomethylation as a Biomarker for Early-Onset Colorectal Cancer - A method for detecting an early-onset of colorectal cancer in a human subject is disclosed herein. The method comprises the steps of: (i) identifying the human subject suspected of suffering from a colorectal cancer, (ii) obtaining one or more biological samples from the human subject; (iii) determining a LINE-1 methylation level for the one or more biological samples; and (iv) comparing the LINE-1 methylation level to a LINE-1 methylation control level, wherein a higher degree of the LINE-1 methylation level is indicative of an early-onset colorectal cancer. | 2012-09-20 |
20120238464 | Biomarkers for Predicting the Recurrence of Colorectal Cancer Metastasis - The present invention includes biomarkers and methods for predicting recurrence-free survival and determination of risk for colorectal liver metastasis (LM) by determining a level of microsatellite instability at tetranucleotide repeats (EMAST) and at mono- and a dinucleotide repeat loci (MSI-L) or a SMARCA | 2012-09-20 |
20120238465 | DRUG SCREENING TARGET FOR ALZHEIMER'S DISEASE AND METHOD OF SCREENING POTENTIAL DRUGS - Drug screening targets and method of screening for potential drugs for treatment or amelioration of Alzheimer's Disease are provided. | 2012-09-20 |
20120238466 | Multiplexed Assay Using Encoded Solid Support Matrices - In a multiplexed assay, each molecule of a plurality of molecules is attached to a support matrix with a substrate adapted for attachment and/or synthesis of molecules and an integrally-formed memory device with an optically-encoded identifier to uniquely identify the molecule attached to the substrate. The molecules are exposed to one or more processing conditions then placed within the path of an optical detector adapted to read the optically-encoded identifier and measure biochemical processes on each support matrix. The support matrices may be singulated to be read by the optical detector one at a time. | 2012-09-20 |
20120238467 | EXOSOME-ASSOCIATED MICRORNA AS A DIAGNOSTIC MARKER - The presently disclosed subject matter provides methods of diagnosis of cancer or adverse pregnancy outcomes in a subject by measuring amounts of one or more microRNAs present in cancer-derived exosomes isolated from a biological sample from the subject. | 2012-09-20 |
20120238468 | METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The present invention discloses a method for diagnosing Irritable Bowel Syndrome (IBS) in a test sample by determining the level of several bacterial taxa in the test sample, comparing this level with the levels of those bacterial taxa in a control sample, and relating the level to a diagnosis of IBS. Additionally, the present invention provides a method for treatment of IBS based on said diagnosis. Also, the invention provides a method for subtyping IBS in a test sample. | 2012-09-20 |
20120238469 | DIAGNOSTIC BIOMARKER TO IDENTIFY WOMEN AT RISK FOR PRETERM DELIVERY - The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers found in women that are at risk for preterm delivery. | 2012-09-20 |
20120238470 | METHOD FOR SCREENING AND QUANTIFYING VARIOUS ENZYME ACTIVITIES USING A GENETIC ENZYME SCREENING SYSTEM - A method of detecting and quantifying various enzymatic activities using a constructed artificial genetic circuit GESS (genetic enzyme screening system) for sensing phenolic compounds and a method of screening a trace of activities of target enzymes from a metagenome using the artificial genetic circuit, thereby securing target enzyme genes. When the method for screening and quantifying target enzymatic activity is used, useful genes can be screened from various genetic communities, including environmental or metagenomic libraries, at a single cell level in high throughput (million/day). Further, the sensitivity of the genetic circuit to phenol derivatives and the expression thereof can be controlled, and thus the genetic circuit can rapidly sense and quantify various enzymatic activities. Thus, the method can be advantageously used in the protein engineering technology for enzyme modification. Particularly, it can quantitatively investigate enzymatic activity, and thus can be applied to molecular evolution technology. | 2012-09-20 |
20120238471 | Ultrasensitive Biochemical Sensing Device and Method of Sensing Analytes - Systems and methods biochemically sense a concentration of a ligand using a sensor having a substrate having a metallic nanoparticle array formed onto a surface of the substrate. A light source is incident on the surface. A matrix is deposited over the nanoparticle array and contains a protein adapted to binding the ligand. A detector detects s-polarized and p-polarized light from the reflective surface. Spacing of nanoparticles in the array and wavelength of light are selected such that plasmon resonance occurs with an isotropic point such that −s and −p polarizations of the incident light result in substantially identical surface Plasmon resonance, wherein binding of the ligand to the protein shifts the resonance such that differences between the −S and −P polarizations give in a signal indicative of presence of the ligand. | 2012-09-20 |
20120238472 | BIOANALYTICAL INSTRUMENTATION USING A LIGHT SOURCE SUBSYSTEM - The invention relates to a light source for irradiating molecules present in a detection volume with one or more selected wavelengths of light and directing the fluorescence, absorbance, transmittance, scattering onto one or more detectors. Molecular interactions with the light allow for the identification and quantitation of participating chemical moieties in reactions utilizing physical or chemical tags, most typically fluorescent and chromophore labels. The invention can also use the light source to separately and simultaneously irradiate a plurality of capillaries or other flow confining structures with one or more selected wavelengths of light and separately and simultaneously detect fluorescence produced within the capillaries or other flow confining structures. In various embodiments, the flow confining structures can allow separation or transportation of molecules and include capillary, micro bore and milli bore flow systems. The capillaries are used to separate molecules that are chemically tagged with appropriate fluorescent or chromophore groups. | 2012-09-20 |
20120238473 | Molecular sensor using temporal discrimination - A sensor device is disclosed, which depends on discrimination in time between groups of binding events of target particles to nano-electrodes. The target particles may be in the liquid phase or in suspension. The nano-electrodes form part of a sensor arrangement having a plurality of sensors. The sensor device is arranged such that different species of target particles arrive at the nano-electrodes at different times, using techniques such as chromatography or application of a field such as an electric, magnetic, or gravitational field. The particles may be labelled or unlabeled. The invention is particularly suited, but not limited, to sensing bioparticles. | 2012-09-20 |
20120238474 | PROBE ARRAY BASE, METHOD FOR MANUFACTURING PROBE ARRAY BASE, METHOD FOR MANUFACTURING PROBE ARRAY - A probe array base including probe-holding portions which are periodically arranged on a solid base member and which have grooves is prepared by anisotropically etching a single-crystalline silicon substrate. Probe solutions are supplied to the probe-holding portions by capillary action from a plurality of tank arrays having a certain cylinder period. This allows a probe array to be completed. The probe array is used as, for example, a DNA or antigen chip, has a high degree of integration, and is capable of holding a constant and sufficient number of probe molecules. | 2012-09-20 |
20120238475 | Methods of Amplifying and Sequencing Nucleic Acids - An apparatus and method for performing rapid DNA sequencing, such as genomic sequencing, is provided herein. The method includes the steps of preparing a sample DNA for genomic sequencing, amplifying the prepared DNA in a representative manner, and performing multiple sequencing reaction on the amplified DNA with only one primer hybridization step. | 2012-09-20 |
20120238476 | ALZHEIMER'S DISEASE DIAGNOSTIC PANELS AND METHODS FOR THEIR USE - Novel compositions, methods, assays and kits directed to a diagnostic panel for Alzheimer's disease are provided. In one embodiment, the diagnostic panel includes one or more proteins associated with Alzheimer's disease. | 2012-09-20 |
20120238477 | METHODS FOR SYNTHESIS OF AN OLIGOPEPTIDE MICROARRAY - An oligopeptide microarray and methods for the synthesis thereof are presented. Further presented is a microarray on a solid support comprising at least about 10,000 oligopeptide features per cm | 2012-09-20 |
20120238478 | PROTEIN MARKERS FOR THE DIAGNOSIS AND PROGNOSIS OF OVARIAN AND BREAST CANCER - Plasma samples of ovarian and breast cancer patients were used to search for markers of cancer, using two-dimensional gel electrophoresis and MALDI TOF mass spectrometry. Truncated forms of cytosolic serine hydroxymethyl transferase (cSHMT), T-box transcription factor 3 (Tbx3) and utrophin were aberrantly expressed in samples from cancer patients, as compared to samples from noncancer cases. Aberrant expression of proteins was validated by immunoblotting of plasma samples with specific antibodies to cSHMT, Tbx3 and utrophin. A cohort of 79 breast and 39 ovarian cancer patients, and 31 individuals who were either healthy or had noncancerous conditions was studied. We observed increased expression of truncated cSHMT, Tbx3 and utrophin in plasma samples obtained from patients at early stages of disease. The results indicate that cSHMT, Tbx3, utrophin and truncated forms thereof can be used as components of multiparameter monitoring of ovarian and breast cancer. | 2012-09-20 |
20120238479 | INULIN AS CORROSION INHIBITOR - Methods of inhibiting corrosion of a metal surface in a well or pipeline are provided. The methods include the steps of: (a) forming a fluid of: (i) an aqueous acid solution; and (ii) inulin; and (b) introducing the fluid into the well or pipeline. The methods have wide application in various kinds of operations involved in the production or transportation of oil and gas, such as acid stimulation or remedial treatment in a pipeline. | 2012-09-20 |
20120238480 | ADDITIVE AGENT, OIL FILTER AND LUBRICATING DEVICE FOR MACHINE - The present invention provides an additive agent to be added to oil and comprising weak basic hydrotalcite. At the time of adding a mixture of hydrotalcite of 1 weight % and water by 3 weight % to the oil where a hydrogen ion exponent is within a range of 6 to 7 for stirring, the weak basic hydrotalcite is hydrotalcite where the obtained oil indicates the hydrogen ion exponent within a range of 6 to 7. Such an additive agent can be accommodated in an oil filter ( | 2012-09-20 |
20120238481 | LUBRICATING OIL COMPOSITION - A lubricating oil composition which is excellent in wear resistance, despite its low phosphorus content, low sulfur content and low sulfuric acid ash content, and which exhibits excellent friction reducing effect even when used for a DLC-treated sliding part, is provided by compounding a specific sulfur-containing compound and a specific polar group-containing compound in a base oil. | 2012-09-20 |
20120238482 | PROCESS FOR THE PREPARATION OF MULTIFUNCTIONAL ADDITIVE FOR AQUEOUS LUBRICANTS - The present invention deals with a process for the preparation of multifunctional additive for aqueous lubricants. These I multifunctional additive for aqueous lubricant comprises of co-polymer having vinyl group containing polyhydric alcohol along with monomer selected from aqueous soluble acrylate co-monomer in different mole fraction for addition polymerization to facilitate the sequencing of monomer in polymer chain. Thus the polymeric molecule has been designed for improving tribological properties i.e. low wear, low friction and EP property of aqueous lubricants. | 2012-09-20 |
20120238483 | ALKOXYLATED POLYAMINES AND POLYETHERAMINE POLYOL COMPOSITIONS FOR FOAM CONTROL - This invention relates to novel compounds derived from the reaction of diamines or polyamines with alkylene oxides. The invention also relates to novel compounds derived from the reaction of amine terminated polyethers with epoxide functional compounds. The novel compounds of the invention are particularly useful as wetting and foam control agents. The disclosed compounds exhibit exceptional antifoaming and defoaming activity while simultaneously reducing the dynamic surface tension when incorporated at low levels in water-based systems. | 2012-09-20 |
20120238484 | PHOSPHATE FUNCTIONALIZED ALKYL POLYGLUCOSIDES USED FOR ENHANCED FOOD SOIL REMOVAL - A method of removing food soil using a cleaning composition including a C | 2012-09-20 |
20120238485 | SURFACTANT COMPOSITION WITH A REDUCTION OF SURFACE TENSION, INTERFACIAL TENSION, AND CRITICAL MICELLE CONCENTRATION USING A PROTEIN-BASED SURFACTANT SYNERGIST - Surfactant-containing compositions are described which include a protein component that has the effect of improving the surface-active properties of the surfactants contained in the compositions. The surfactant-containing compositions having the protein component demonstrate significantly lower critical micelle concentrations (CMC), reduced surface tensions, and reduced interfacial tensions than do comparable compositions having no protein component. In addition, the surfactant-containing compositions having the protein component has the effect of converting greasy waste contaminants to surface active materials. | 2012-09-20 |
20120238486 | Novel Aldehydes and Nitriles from Isophorone and the Use Thereof in Perfumery | 2012-09-20 |
20120238487 | POLYMER COMPOSITION USEFUL AS A PHARMACEUTICAL CARRIER - A polymer having a structure according to the following formula (I): wherein: A represents a hydrophilic group; B represents a hydrophobic aromatic group such as 5-dimethylamino-1-naphthalenesulfonyl (Dansyl), 9-fluorenylmethoxy carbonyl (Fmoc) and naphthalene (Naphth); D and E independently represent amine groups; F represents an amine group, the amine group being substituted with a B group and an A group, or the amine group being a quaternary ammonium moiety; wherein W, X, Y and Z each independently have values greater than or equal to (1), especially in the range of (1) to (10). | 2012-09-20 |
20120238488 | COMPOUNDS AND METHODS FOR TREATING NEOPLASIA - The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia. | 2012-09-20 |
20120238489 | METHOD FOR IMPROVING FUNCTIONAL PROPERTIES BY MEANS OF PULSED LIGHT, SAMPLES WITH IMPROVED FUNCTIONAL PROPERTIES AND USES THEREOF - Disclosed is a method for improving the functional properties of a sample, which comprises at least one component that can be modified upon absorbing ultraviolet light, the method including using pulsed light with an emission spectrum of 190-1100 nm and a high content of ultraviolet light to modify the component. The method makes it possible to obtain samples with improved functional properties (hydration, glass transition, solubility, water retention capacity, oil retention capacity, thickening, dispersing, emulsifying, foaming or gelling properties, film formation properties, bulking agent properties, surface properties (wettability, adhesion, etc.)) which are used in the food industry, the cosmetics industry, the pharmaceutical industry, the biomedical industry, the biotechnological industry, the chemical industry and in other industries. | 2012-09-20 |
20120238490 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS - Embodiments described herein are directed to methods for the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, including atherosclerosis and non-insulin dependent diabetes. In addition, embodiments are directed to methods of treating coronary heart disease and metabolic syndrome. Embodiments are also directed to neurotensin analogs. In embodiments, the neurotensin analogs may be capable of binding to neurotensin receptors and, upon binding, may modulate the levels of lipids in subjects. | 2012-09-20 |
20120238491 | IMMUNOLOGICALLY ACTIVE LIPOPEPTIDES AND METHODS FOR USE THEREOF - The present invention relates to the isolation and structure elucidation of 1-peptidyl-2-arachidonoyl-3-stearoyl glyceride (pDAG) as an active chemical entity in the caprine serum fraction, and the discovery of the innate immune modulating activity of pDAG as an endogenous damage associated molecular pattern | 2012-09-20 |
20120238492 | FISH PROTEIN HYDROLYSATE FOR THE USE THEREOF IN INHIBITING WEIGHT GAIN AND/OR WEIGHT LOSS - The present invention relates to fish protein hydrolysates for the use thereof in inducing weight loss and in limiting and/or inhibiting weight gain. The invention also relates to such hydrolysates in preventing and/or treating excessive weight and/or health problems linked to excessive weight. | 2012-09-20 |
20120238493 | GLUCAGON ANALOGS EXHIBITING GIP RECEPTOR ACTIVITY - Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range. | 2012-09-20 |
20120238494 | METHODS FOR REDUCING GNRH-POSITIVE TUMOR CELL PROLIFERATION - A method for recognizing and evaluating the presence and function of GnRH receptors on tumor cells including those originating in the brain and/or nervous system and/or the meninges and/or reactive neuroglia cells and/or primitive neuroectodermal tumor cells and/or on Kaposi sarcoma is provided. Furthermore, a method for reducing degenerate GnRH-positive tumor cells and/or for decreasing cellular replication of the above GnRH-positive tumor cells comprising administering to a cell or to a subject a replication decreasing amount of a GnRH agonist and/or GnRH antagonist and/or an erythropoietin agonist, and/or a thrombopoietin agonist, and/or a endothelin antagonist and/or a gonadotropin inhibiting hormone agonist is also provided. Furthermore, a diagnostic kit for detecting GnRH receptors on tumor cells according to the present methods is disclosed. | 2012-09-20 |
20120238495 | Novel Cellular Factor-Containing Solution Compositions - The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof. | 2012-09-20 |
20120238496 | FUSION PROTEIN REGULATING PLASMA GLUCOSE AND LIPID, ITS PREPARATION METHOD AND USE - Provided is a fusion protein, which comprises human fibroblast growth factor 21 and glucagon-like-peptide-1 or its analogs. Also provided is the medicament composition comprising the fusion protein, which can be used for treating or preventing obesity, diabetes, hyperglycemia and hyperlipidemia etc. | 2012-09-20 |
20120238497 | GLP-1 FUSION PEPTIDES, THEIR PRODUCTION AND USE - The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for preparing a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders. | 2012-09-20 |
20120238498 | Agent for the treatment of alopecia - It is an object of the present invention to provide a new agent for the treatment of alopecia, the agent being not only effective and safe for, in particular, alopecia areata, androgenetic alopecia in a male, androgenetic alopecia in a female, female pattern alopecia, postpartum alopecia, seborrheic alopecia, alopecia pityroides, senile alopecia, cancer chemotherapy drug-induced alopecia, and alopecia due to radiation exposure, but also effective for a target having resistance to treatment with minoxidil or finasteride, there being no side effects such as an itching sensation, irritation, or feminization, and no contraindications, the agent suppressing dandruff or having a therapeutic effect for white hair, and the therapeutic effect for alopecia being maintained for a long period even when use of the agent is stopped. | 2012-09-20 |
20120238499 | METHODS OF MODULATING APOPTOSIS BY ADMINISTRATION OF RELAXIN AGONISTS OR ANTAGONISTS - The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist to a subject. | 2012-09-20 |
20120238500 | REGULATION OF EPITHELIAL TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO - The present application is directed to the discovery that preparations of hedgehog polypeptides can be used to control the formation and/or maintenance of epithelial tissue. | 2012-09-20 |
20120238501 | Modulation Of Osteoclast Differentiation - The present invention concerns the use of an aquaprin-9 (AQP-9) modulator for the preparation of a pharmaceutical composition for treating or preventing a pathological condition associates with unbalanced osteoclast differentiation. In accordance with one embodiment, the modulator is an AQP-9 inhibitor. An example of an inhibitor is phloretin which was shown to inhibit osteoclast differentiation following induction of bone marrow cells with RANKL. The invention also concerns methods for modulating osteoclast differentiation, methods for treating pathological conditions associated with unbalanced osteoclast differentiation as well as pharmaceutical composition comprising such modulators. | 2012-09-20 |
20120238502 | ANTI-FIBROTIC HYDROGEL COMPOSITIONS - A cross linked recombinant gelatin composition for the controlled release of a cellular adhesion inhibitory agent. | 2012-09-20 |
20120238503 | HUMAN LAMININ ALPHA2 CHAIN LG3 DOMAIN AND ACTIVE PEPTIDES PROMOTING CELL ADHESION, SPREADING, MIGRATION, AND NEURITE OUTGROWTH - The present invention relates to human laminin α2 chain LG3 domain and active peptides promoting cell adhesion, spreading, migration, and neurite outgrowth. More particularly, it was found that when nerve cells are incubated using human laminin α2 chain LG3 domain and active peptides in the LG3 domain, cell adhesion, spreading, migration, and neurite outgrowth of nerve cells promote and the promotion of cell adhesion, spreading, migration, and neurite outgrowth of nerve cells are integrin-mediated and achieved by the activation of PKCδ and FAK phosphorylation. Thus, the present invention can be very useful for researches on cell adhesion, spreading, migration, and neurite outgrowth activities of cells which are focused on nerve cells and mediated by various extracellular matrix proteins including laminin, manufacture of artificial nerve conduits, burns treatment, wounds treatment, and tissue regeneration. | 2012-09-20 |
20120238504 | Stable Formulations of Botulinum Toxin in Hydrogels - The invention includes liquid formulations of botulinum toxin, including hydrogel formulations that are stable to storage in liquid form at standard refrigerator temperatures for at least 1-2 years and to storage at higher temperatures for at least 6 months. The invention also includes methods of treatment using such formulations for various therapeutic and cosmetic purposes. | 2012-09-20 |
20120238505 | Medicaments - The present invention relates to the use of a peptide, or derivative thereof of general formula X1-X2-X3-ThT-X4-LyS-X5-ATg-X6 for promoting accelerated wound healing with reduced scarring. X1 is Ala or Gly; X2 is Tyr or Phe; X3, X4 and X5 are independently selected from the group comprising Met, He, Leu and Val; and X6 is selected from the group comprising Asp, Gln and Glu. | 2012-09-20 |
20120238506 | ACACIA MACROSTACHYA SEED EXTRACT AND COMPOSITIONS CONTAINING SAME - The invention relates to a composition containing an extract of seeds of | 2012-09-20 |
20120238507 | ALPHA HELICAL MIMICS, THEIR USES AND METHODS FOR THEIR PRODUCTION - Disclosed are short chain peptides that are constrained to adopt an alpha helicial conformation and their use as alpha helical scaffolds for directing amino acid side chains into positions analogous to those found in longer chain alpha helical peptides. Also disclosed is the use of these peptides for attaching peptidic or non-peptidic appendages in order to mimic side chains of longer alpha helical peptides. The peptides find use in mimicking naturally occurring peptides or proteins or in preparing new materials. | 2012-09-20 |
20120238508 | Methods for Promoting Wound Healing and/or Reducing Scar Formation - The present invention provides methods for promoting wound healing and/or reducing scar formation, by administering to an individual in need thereof one or more of the heat shock protein 20-derived polypeptides disclosed herein. | 2012-09-20 |
20120238509 | UROCORTIN 2 ANALOGS AND USES THEREOF - Disclosed are polypeptides that are analogs of urocortin 2 that have pharmacological activity similar to urocortin 2 but have improved water solubility compared to urocortin 2, and pharmaceutical compositions of the polypeptides of the present invention. Also disclosed are polynucleotides encoding the polypeptides, and methods of treating pathophysiological states employing pharmaceutical compositions of the polypeptides and polynucleotides of the present invention. In addition, disclosed are vectors and host cells that include a nucleic acid encoding a polypeptide of the present invention, and kits that include pharmaceutical compositions of the present invention. | 2012-09-20 |
20120238510 | CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR - Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition. | 2012-09-20 |
20120238511 | 2-DEOXY-D-GLUCOSE FORMULATIONS FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES - Pharmaceutical compositions containing 2-deoxy-D-glucose (2-DG) and methods of use for promoting neurological health and prevention of age-related neurodegeneration, such as Alzheimer's disease (AD), have been developed. The compositions may be formulated such that the composition, or the compound when release from the composition, crosses the blood-brain-barrier and promote neurotrophism and neuroprotection mechanisms in the brain. 2-DG can be administered alone or in combination with one or more additional therapeutic, diagnostic, and/or prophylactic agents. The compositions described herein can be administered orally, enterally, transdermally, transmucosally, intranasally or parenterally, in a dosage effective to prevent or alleviate neuronal damage, effect neuronal regeneration or sustain viability, increase expression of anti-apoptotic proteins, and/or decrease indicators of Alzheimer's Disease. The formulations can be formulated for daily, sustained, delayed or weekly/monthly administration. | 2012-09-20 |
20120238512 | ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE - The present invention relates compounds of the formula (I) oligosaccharide-spacer-A (I), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa activity per se; the spacer is an essentially pharmacologically inactive flexible linking residue having a chain length of 10 to 70 atoms; A is the residue —CH[NH—SO | 2012-09-20 |
20120238513 | METHOD FOR INHIBITING ACTIVATION OF MACROPHAGES - Provided is a method for inhibiting the activation of macrophages in a subject, comprising administrating to the subject an effective amount of an active component selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, and a pharmaceutically acceptable ester of the compound, and combinations thereof: | 2012-09-20 |
20120238514 | NOVEL CRYSTALLINE HETEROAROMATIC FLUOROGLYCOSIDE HYDRATES, PHARMACEUTICALS COMPRISING THESE COMPOUNDS AND THEIR USE - The invention relates to crystalline hydrates of the formula I | 2012-09-20 |
20120238515 | METHODS FOR PREVENTING OR TREATING SARCOPENIA AND MUSCLE ATROPHY IN ANIMALS - The invention provides methods for one or more of preventing or treating sarcopenia and muscle atrophy in animals. The methods comprise administering isoflavones to the animals, preferably in amounts of from about 0.001 to about 10 g/kg/day. | 2012-09-20 |
20120238516 | GRANULATED ANTHELMINTIC PREPARATIONS AND DELIVERY SYSTEMS - The present invention relates to anthelmintic compositions comprising two or more anthelmintic active agents selected from one or more of the following groups; imidazothiazoles such as levamisole, benzimidazoles such as oxfendazole, or fenbendazole, macrocylic lactones such as ivermectin or avermectin, salicylanilides, and praziquantel. The composition being in the form of stable granules that are readily dispersible in water so as to provide a homogenous mixture of the anthelmintic agents suitable for administration. Methods of preparing the composition are also described. | 2012-09-20 |
20120238517 | INSECTICIDAL COMPOUNDS BASED ON ISOAZOLINE DERIVATIVES - The present invention relates to compounds of formula (I): Wherein A | 2012-09-20 |
20120238518 | DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER - Disclosed is a method of treating cancer in a patient comprising administering to the patient an effective amount of a diazeniumdiolated (N | 2012-09-20 |
20120238519 | OPHTHALMIC COMPOSITION CONTAINING ALGINIC ACID OR SALT THEREOF - An ophthalmic composition that, despite containing alginic acid and/or a salt thereof, has improved tackiness during use and provides a satisfactory use feeling. The composition has an improved ability to remain on the eye mucosa. The ophthalmic composition contains (A) alginic acid and/or a salt thereof in combination with (B) hyaluronic acid and/or a salt thereof. | 2012-09-20 |
20120238520 | Novel Medical Use - The present invention relates to a compound which is (2R,3R,4S,5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol | 2012-09-20 |
20120238521 | Compositions and Methods for the Treatment of Musculoskeletal Related Diseases and Disorders Using Metal Ion-Citrate Analog Complexes - The invention is directed to a composition and associated method for the treatment of musculoskeletal related disorders and diseases. In particular, the present invention provides a class of citrate compounds that can be used to for the treatment of diseases/disorders characterized by the degeneration of musculoskeletal tissues including menisci, bone, articular cartilage, and soft tissues. Examples of suitable citrate and citrate analog compounds include citrates having the following base formula (I): | 2012-09-20 |
20120238522 | CAROTENOID-CONTAINING COMPOSITIONS AND METHODS - The present invention is directed to carotenoid compositions and methods for inhibiting the growth of pathogenic bacteria or for preventing or treating bacterial infections in subjects by administration of an effective amount of astaxanthin and beta-carotene. | 2012-09-20 |
20120238523 | GLYCOSAMINOGLYCAN MIXTURES - The present invention relates to osteoblast derived glycosaminoglycan mixtures and to their use in one or more of: inhibition of osteoclastogenesis, enhancement of proliferation of osteoblasts, and/or the treatment or prevention of bone fracture or bone deterioration. | 2012-09-20 |
20120238524 | WATER-SOLUBLE POLYSACCHARIDE ETHERS AND THEIR USE - The invention relates to modified polysaccharide ethers having a weight-averaged molecular weight of 40000 to 50000 g/mole, zero shear viscosity of more than 10 Pas, and pseudoplasticity of more than 20, obtainable by reacting cellulose-based polysaccharide ether(s) with at least one mesogenic modification agent or modified polysaccharide ethers, obtainable by reacting polysaccharide ether(s) selected from the group consisting of hydroxypropylmethyl cellulose (HPMC), hydroxyethylmethyl cellulose (HEMC), methyl cellulose, and cellulose ethers with methyl and/or ethyl and/or propyl groups and mixtures thereof, with at least one mesogenic modification agent. Said substances can be used to produce gel-like to stable aqueous preparations having viscoelastic flow properties, which are suited for use in the human body, particularly within the scope of ophthalmologic procedures. | 2012-09-20 |
20120238525 | PERITONEAL DIALYSIS SOLUTIONS COMPRISING GLUCOSE POLYMERS - Peritoneal dialysis solutions including a glucose polymer and methods of using the dialysis solutions are disclosed herein. In a general embodiment, the peritoneal dialysis solution includes a glucose polymer in an amount to provide an increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed compared to conventional dialysis solutions containing icodextrin as the active pharmaceutical ingredient. The increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed is obtained by providing specific combinations of weight-average molecular weight, polydispersity index and concentration of the glucose polymer in the dialysis solution. | 2012-09-20 |
20120238526 | ACONITINE COMPOUNDS, COMPOSITIONS, USES, AND PREPARATION THEREOF - Compound derivatives of aconitine are provided, in particular derivatives that modulate the activity of sodium channels. Also provided are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier. The subject compounds are useful in treatments, including treatments to modulate neuronal activity or to bring about muscular relaxation. The compounds also find use in the treatment of subjects suffering from a voltage-gated sodium channel-enhanced ailment or from pain. Further methods are provided for the preparation of the aconitine derivatives. | 2012-09-20 |
20120238527 | ORGANOPHOSPHORUS DERIVATIVES AND USE THEREOF AS UNCOUPLING AGENTS - The present invention relates to an organophosphonium derivative of the mean general formula (1), where n is a number comprised between 4 and 20, preferably between 5 and 10, m is a number between 0 and 10, preferably between 0 and 1, and Y is an anion. | 2012-09-20 |
20120238528 | NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES - The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders. | 2012-09-20 |
20120238529 | TRIPTOLIDE PRODRUGS - The invention provides compounds of formula (I): or a salt thereof. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods using the compounds of formula I. | 2012-09-20 |
20120238530 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES - The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative. | 2012-09-20 |
20120238531 | ISOXAZOLIDINE DERIVATIVES - Anti-inflammatory and antiallergic compounds of the glucocorticosteroid series according to formula (I) defined herein are useful for treating diseases of the respiratory tract characterized by airway obstruction. | 2012-09-20 |
20120238532 | TREATMENT OF HUMAN OSTEOSARCOMA - The present invention describes the combination of cucurbitacin (CuB) with methotrexate (MTX) for the treatment of cancers, including osteosarcoma. It was discovered that CuB and MTX have synergistic activity against osteosarcoma, which reduces toxicities associated with both chemotherapeutic agents. The present invention also describes the use of CuB for the treatment of osteosarcoma. | 2012-09-20 |
20120238533 | (Heteroarylmethyl) Thiohydantoins as anticancer drugs - The invention refers to the use of androgen receptor antagonists for the treatment and/or prevention of fibroids, also known as uterine leiomyoma, leiomyomata. Particularly, the invention refers to the use of an androgen receptor antagonist being any one of the compounds according to the following list: cyproterone acetate, oxendolone, chlormadinone acetate, spironolactone, osaterone acetate, dienogest, flutamide, hydroxyflutamide, nilutamide, bicalutamide, RU 58841, LGD-2226, MDV3100, BMS-641988, BMS-779333, or 4-(3-{[6-(2-hydroxy-2-methylpropoxy)pyridin-3-yl]methyl}-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (thioxoimidazolidine derivative) for the treatment of fibroids. | 2012-09-20 |
20120238534 | ORAL SUSPENSION OF PREDNISOLONE ACETATE - The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation. | 2012-09-20 |
20120238535 | Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes - A new topical formulation is provided, with a high chemical stability, of for example a low dose clobetasol propionate, suitable for the topical treatment of skin and mucous membrane conditions associated with disorders including psoriasis, eczema, and other forms of dermatitis and also topical use associated with he mouth, such as lichen planus. The formulation includes an aqueous vehicle of based on propylene glycol as a solvent and moisture-retaining agent, and macrogol-glycerol hydroxystearate as a non-ionic emulsifier, being capable of holding surprisingly low concentrations of clobetasol. The vehicle holds concentrations about 0.005% to about 0.05% by weight of 17-clobetasol propionate, more preferably about 0.02 to 0.025%, even more preferably 0.025% by weight of 17-clobetasol propionate. The formulation has a good chemical stability, resulting in a long durability. | 2012-09-20 |
20120238536 | Method for Treating Retinal Conditions Using an Intraocular Tamponade - Composition comprising at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, said composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably comprised between 0.90 and 1, or a density above 1 more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of said composition. | 2012-09-20 |
20120238537 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 2012-09-20 |